Madhya Pradesh Online Journal

Atopic Dermatitis Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – Connect Biopharma, Pfizer, Allakos, Novartis, BioMimetix

 Breaking News
  • No posts were found

Atopic Dermatitis Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – Connect Biopharma, Pfizer, Allakos, Novartis, BioMimetix

May 10
00:53 2023
Atopic Dermatitis Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Connect Biopharma, Pfizer, Allakos, Novartis, BioMimetix
DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Atopic Dermatitis.

DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Atopic Dermatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atopic Dermatitis Market Forecast

 

Some of the key facts of the Atopic Dermatitis Market Report: 

  • The Atopic Dermatitis market size was valued approximately USD 15,206 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In November 2022, The first cohort of the Phase IIa clinical study for AB-101a, a topical treatment option for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old, has finished, according to an announcement from Alphyn Biologics. Patients without bacterial infections, which are occasionally linked to AD, were enrolled in the first cohort. Top-line outcomes are anticipated in around eight weeks
  • In September 2022, Patients in a Phase Ib trial to assess the safety and effectiveness of si-544 in those with mild to severe atopic dermatitis have started receiving doses, according to selectION
  • Key Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others
  • Key Atopic Dermatitis Therapies: Bermekimab, Etrasimod, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, and others
  • The Atopic Dermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atopic Dermatitis pipeline products will significantly revolutionize the Atopic Dermatitis market dynamics.

 

Atopic Dermatitis Overview

Atopic dermatitis (AD), commonly referred to as atopic eczema, is a form of skin inflammation. It causes skin that is scratchy, red, swollen, and cracked. The damaged sites may leak a clear fluid that thickens over time. Although the disorder can strike at any age, it usually first manifests in childhood and varies in severity throughout time. Much of the body may be impacted in infants under the age of one year.

 

Get a Free sample for the Atopic Dermatitis Market Report –

https://www.delveinsight.com/sample-request/atopic-dermatitis-market

 

Atopic Dermatitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Atopic Dermatitis Epidemiology Segmentation:

The Atopic Dermatitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Atopic Dermatitis
  • Prevalent Cases of Atopic Dermatitis by severity
  • Gender-specific Prevalence of Atopic Dermatitis
  • Diagnosed Cases of Episodic and Chronic Atopic Dermatitis

 

Download the report to understand which factors are driving Atopic Dermatitis epidemiology trends @ Atopic Dermatitis Epidemiology Forecast

 

Atopic Dermatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atopic Dermatitis market or expected to get launched during the study period. The analysis covers Atopic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Atopic Dermatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Atopic Dermatitis Therapies and Key Companies

  • Bermekimab: Janssen Pharmaceutical
  • Etrasimod: Arena Pharmaceuticals
  • FB825: Oneness Biotech
  • Lebrikizumab: Eli Lily
  • Nemolizumab: Galderma
  • B244: AOBiome
  • Ruxolitinib: Incyte
  • Difelikefalin: Cara Therapeutics

 

Discover more about therapies set to grab major Atopic Dermatitis market share @ Atopic Dermatitis Treatment Market

 

Atopic Dermatitis Market Drivers

  • Rising prevalence of Atopic Dermatitis
  • Escalating expenditure on healthcare
  • Approvals of JAK inhibitors
  • Potential Emerging Therapies for Atopic Dermatitis and pruritus
  • Increasing awareness about the condition

 

Atopic Dermatitis Market Barriers

  • Over-the-counter medications
  • Outdated treatment recommendations
  • Poor prognosis and treatment adherence
  • Lack of timely diagnosis
  • Management of Atopic Dermatitis in the primary care setting

 

Scope of the Atopic Dermatitis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others
  • Key Atopic Dermatitis Therapies: Bermekimab, Etrasimod, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, and others
  • Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
  • Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Atopic Dermatitis Unmet Needs, KOL’s views, Analyst’s views, Atopic Dermatitis Market Access and Reimbursement 

 

To know more about Atopic Dermatitis companies working in the treatment market, visit @ Atopic Dermatitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Atopic Dermatitis Market Report Introduction

2. Executive Summary for Atopic Dermatitis

3. SWOT analysis of Atopic Dermatitis

4. Atopic Dermatitis Patient Share (%) Overview at a Glance

5. Atopic Dermatitis Market Overview at a Glance

6. Atopic Dermatitis Disease Background and Overview

7. Atopic Dermatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Atopic Dermatitis 

9. Atopic Dermatitis Current Treatment and Medical Practices

10. Atopic Dermatitis Unmet Needs

11. Atopic Dermatitis Emerging Therapies

12. Atopic Dermatitis Market Outlook

13. Country-Wise Atopic Dermatitis Market Analysis (2019–2032)

14. Atopic Dermatitis Market Access and Reimbursement of Therapies

15. Atopic Dermatitis Market Drivers

16. Atopic Dermatitis Market Barriers

17.  Atopic Dermatitis Appendix

18. Atopic Dermatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services